Brief: SynAct Pharma Q4 Sales SEK 0
23/02/2024 06:50
Feb 23 (Reuters) - SynAct Pharma Q4 cash flow from operating activities SEK -20.395 million. * Q4 adjusted EPS SEK -2.58 * Q4 net income SEK -90.543 million * Q4 operating expenses SEK 91.062 million
Recent news on SynAct Pharma AB
See all newsSweden's SynAct Pharma Q3 net loss narrows as expenses fall
Brief: SynAct Pharma Q3 Net Income SEK -32.177 Million
Brief: SynAct Pharma Signs First Commercial Partnership For Resomelagon
Brief: WHO Names Resomelagon Among Key Dengue Drug Candidates
Brief: SynAct Pharma Says Advance Analysis Supports Phase 3 Development